Conference Coverage

Keloids: Cutting is never enough


 

EXPERT ANALYSIS FROM SDEF HAWAII DERMATOLOGY SEMINAR

“I’ve found [5-fluorouracil] to be of limited use. I think corticosteroid is the heavy lifter. I’d prefer not to be injecting an antimetabolite into somebody if I can help it,” Dr. Baldwin said.

She reported receiving research funding from Dermira, Galderma, La Roche-Posay, Novan, and Valeant; and serving as a consultant and/or on a speakers’ bureau for Allergan, Bayer, Encore, Johnson & Johnson, Mayne, and Sun.

SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company.

Pages

Recommended Reading

Make The Diagnosis - April 2018
MDedge Dermatology
Bacteria seen as potential lupus triggers
MDedge Dermatology
Pilot study: Topical anticholinergic improved axillary hyperhidrosis in teens, young adults
MDedge Dermatology
Lenalidomide yields responses in a rare cutaneous lymphoma
MDedge Dermatology
From weekend warriors to pros, athletes are plagued by skin disorders
MDedge Dermatology
Prioritize topical treatments in pregnant women
MDedge Dermatology
Why do people act that way?
MDedge Dermatology
Recently approved SK treatment spares melanocytes in preclinical study
MDedge Dermatology
Grind it out
MDedge Dermatology
Noninvasive 1060-nm diode laser found effective for axillary hyperhidrosis
MDedge Dermatology